Metformin during pregnancy reduces insulin, insulin resistance, insulin secretion, weight, testosterone and development of gestational diabetes: prospective longitudinal assessment of women with polycystic ovary syndrome from preconception throughout pregnancy
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
BACKGROUND: In a prospective observational study of 42 pregnancies in 39 Caucasian women (age 30 +/- 4 years) with polycystic ovary syndrome (PCOS), we examined effects of metformin on maternal insulin, insulin resistance (IR), insulin secretion (IS), weight gain, development of gestational diabetes (GD), testosterone and plasminogen activator inhibitor activity. We assessed the hypothesis that diet-metformin (MET) lessens the physiological gestational increase in IR and reduces gestational weight gain, thus reducing GD. METHODS: Preconception, in an out-patient clinical research centre, MET 1.5 (eight pregnancies) to 2.55 g/day (34 pregnancies) was started. Women with body mass index <25 or >or=25 kg/m(2) were given a 2000 or 1500 calorie/day, high-protein (26% of calories), low-carbohydrate (44%) diet. Calorie restrictions were dropped after conception. RESULTS: On MET, GD developed in three out of 42 pregnancies (7.1%). Median entry weight (94.5 kg) fell to 82.7 on MET at the last preconception visit (P = 0.0001), fell further to 81.6 during the first trimester, was 83.6 in the second trimester, and 89.1 kg in the third trimester. Median weight gain during pregnancy was 3.5 kg. The median percentage reduction in serum insulin was 40% on MET at the last preconception visit; insulin did not increase in the first or second trimesters (P > 0.05), and rose 10% in the third trimester. The median percentage reduction in HOMA IR was 46% on MET at the last preconception visit; IR did not increase (P > 0.05) in the first, second or third trimesters. HOMA insulin secretion fell 45% on MET at the last preconception visit, did not increase in the first trimester, rose 24% in the second trimester, and rose 109% in the third trimester. Testosterone fell 30% on MET at the last preconception visit (P = 0.01) and then rose 74, 61 and 95% during trimesters 1, 2 and 3; median testosterone during the third trimester did not differ from pre-treatment levels. CONCLUSIONS: By reducing preconception weight, insulin, IR, insulin secretion and testosterone, and by maintaining these insulin-sensitizing effects throughout pregnancy, MET-diet reduces the likelihood of developing GD, and prevents androgen excess for the fetus.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Velazquez, E. M., Mendoza, S., Hamer, T., Sosa, F., & Glueck, C. J. (1994) · Metabolism · doi:10.1016/0026-0495(94)90209-7 · Cited by 865 · cited 2×
“A second benefit of metformin during pregnancy in women with PCOS is its testosterone-lowering effect, which, like prevention of weight gain, is probably mediated through its insulin-sensitizing action ( Velazquez et al., 1994, 1997 ).”
BackgroundSelf-citationCarbohydrate and lipid metabolism in pregnancy: normal compared with gestational diabetes mellitus
Butte, N. F. (2000) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/71.5.1256s · Cited by 826
Screening criteria for high-risk gestational diabetic patients
O'Sullivan, J. B., Mahan, C. M., Charles, D., & Dandrow, R. V. (1973) · American Journal of Obstetrics and Gynecology · doi:10.1016/s0002-9378(16)33833-9 · Cited by 478
Early metabolic abnormalities in adolescent girls with polycystic ovarian syndrome
Lewy, V. D., Danadian, K., Witchel, S. F., & Arslanian, S. (2001) · The Journal of Pediatrics · doi:10.1067/mpd.2001.109603 · Cited by 298 · cited 3×
“Lewy et al. (2001) studied 12 obese girls with PCOS, average age 12 years.”
BackgroundInfluentialNew Approach to Polycystic Ovary Syndrome and Other Forms of Anovulatory Infertility
Laven, J. S. E., Imani, B., Eijkemans, M. J. C., & Fauser, B. C. J. M. (2002) · Obstetrical & Gynecological Survey · doi:10.1097/00006254-200211000-00022 · Cited by 235 · cited 2×
“Having selected the cohort on the basis of previous PCOS diagnostic criteria (Kawadzki and Dunaif, 1992; Glueck et al., 2002c,d), we also examined the diagnosis of PCOS in the subset of 34 women having polycystic ovaries documented by pelvic ultrasound and/or laparotomy (Table I, bottom 4 rows), using criteria of the…”
MethodInsulin Secretion during and after Pregnancy in Patients with Gestational Diabetes Mellitus1
Homko, C., Sivan, E., Chen, X., Reece, E. A., & Boden, G. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.2.7137 · Cited by 217
Obstetric outcome in women with polycystic ovarian syndrome
Mikola, M. (2001) · Human Reproduction · doi:10.1093/humrep/16.2.226 · Cited by 206
Metformin, pre-eclampsia, and pregnancy outcomes in women with polycystic ovary syndrome
Glueck, C. J., Bornovali, S., Pranikoff, J., Goldenberg, N., Dharashivkar, S., & Wang, P. (2004) · Diabetic Medicine · doi:10.1111/j.1464-5491.2004.01251.x · Cited by 115
Self-citation
Cited by
Lim, S. S., Davies, M. J., Norman, R. J., & Moran, L. J. (2012) · Human Reproduction Update · doi:10.1093/humupd/dms030 · Cited by 939
Palomba, S., Falbo, A., Zullo, F., & Orio, F. (2009) · Endocrine Reviews · doi:10.1210/er.2008-0030 · Cited by 426
Qin, J. Z., Pang, L. H., Li, M. J., Fan, X. J., Huang, R. D., & Chen, H. Y. (2013) · Reproductive Biology and Endocrinology · doi:10.1186/1477-7827-11-56 · Cited by 317
“As a result, PCOS is not only related to metabolic abnormalities, menstrual irregularity or infertility as previously reported, but becoming increasingly recognized the problems of gestational diabetes (GDM), pregnancy-induced hypertension, preeclampsia, premature delivery rate, neonatal birth weight, caesarean sectio…”
BackgroundVanky, E., Stridsklev, S., Heimstad, R., Romundstad, P., Skogøy, K., Kleggetveit, O., Hjelle, S., von Brandis, P., Eikeland, T., Flo, K., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-0853 · Cited by 315
“2) Systolic blood pressure (mm Hg) 119 (12) 118 (11) Diastolic blood pressure (mm Hg) 74 (12) 73 (10) Heart rate (beats/min) 76 (10) 74 (10) Fasting glucose (mg/dl) 83 (9) 83 (11) 2-h glucose (mg/dl) 101 (27) 101 (29) Gestational length at inclusion (d) 74 (13) 75 (11) GDM at inclusion (no.”
Placental passage of metformin in women with polycystic ovary syndrome
Vanky, E., Zahlsen, K., Spigset, O., & Carlsen, S. M. (2005) · Fertility and Sterility · doi:10.1016/j.fertnstert.2004.11.051 · Cited by 245
Metadata
- Authors
- Glueck, C. J.
- Venue
- Human Reproduction
- Publisher
- Oxford University Press (OUP)
- Published
- 2004-01-29
- Volume
- 19
- Issue
- 3
- Pages
- 510-521
- ISSN
- 0268-1161 (ISSN-L)
- 1460-2350
- OpenAlex
- W2097617267
- Cited by
- 183
- References
- 8
- FWCI
- 23.79
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.